Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Morgan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of the American Pharmacists Association : Japha|June 20, 2025
Prescription Drug Pricing on a Bitcoin Standard: Rethinking Healthcare Affordability Amid Fiat InflationJames Wong, Amar Lunagaria, Nathan Morgan, et al.
Journal of the American Chemical Society|November 21, 2025
Accurately Predicting Solubility Curves via a Thermodynamic Cycle, Machine Learning, and Solvent EnsemblesEmad Al Ibrahim, Nathan Morgan, Simon Müller, et al.
Journal of the American Chemical Society|June 8, 2022
<i>Aza</i>-Quasi-Favorskii Reaction: Construction of Highly Substituted Aziridines through a Concerted Multibond Rearrangement ProcessPadmanabha V Kattamuri, Jidong Zhao, Tamal Kanti Das, et al.
Journal of the American Chemical Society|July 24, 2023
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from CubanesJeong-Yu Son, Santeri Aikonen, Nathan Morgan, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2011
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active siteWei Wang, Pratik Devasthale, Aiying Wang, et al.
Journal of Medicinal Chemistry|August 23, 2013
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)Pratik Devasthale, Ying Wang, Wei Wang, et al.
Accounts of Chemical Research|May 21, 2025
ASKCOS: Open-Source, Data-Driven Synthesis PlanningZhengkai Tu, Sourabh J Choure, Mun Hong Fong, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2008
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonistsWei Wang, Pratik Devasthale, Dennis Farrelly, et al.
Bioorganic & Medicinal Chemistry Letters|February 10, 2009
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonistsHao Zhang, Denis E Ryono, Pratik Devasthale, et al.
Journal of Medicinal Chemistry|February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesWei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of the American Pharmacists Association : Japha|June 20, 2025
Prescription Drug Pricing on a Bitcoin Standard: Rethinking Healthcare Affordability Amid Fiat InflationJames Wong, Amar Lunagaria, Nathan Morgan, et al.
Journal of the American Chemical Society|November 21, 2025
Accurately Predicting Solubility Curves via a Thermodynamic Cycle, Machine Learning, and Solvent EnsemblesEmad Al Ibrahim, Nathan Morgan, Simon Müller, et al.
Journal of the American Chemical Society|June 8, 2022
<i>Aza</i>-Quasi-Favorskii Reaction: Construction of Highly Substituted Aziridines through a Concerted Multibond Rearrangement ProcessPadmanabha V Kattamuri, Jidong Zhao, Tamal Kanti Das, et al.
Journal of the American Chemical Society|July 24, 2023
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from CubanesJeong-Yu Son, Santeri Aikonen, Nathan Morgan, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2011
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active siteWei Wang, Pratik Devasthale, Aiying Wang, et al.
Journal of Medicinal Chemistry|August 23, 2013
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)Pratik Devasthale, Ying Wang, Wei Wang, et al.
Accounts of Chemical Research|May 21, 2025
ASKCOS: Open-Source, Data-Driven Synthesis PlanningZhengkai Tu, Sourabh J Choure, Mun Hong Fong, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2008
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonistsWei Wang, Pratik Devasthale, Dennis Farrelly, et al.
Bioorganic & Medicinal Chemistry Letters|February 10, 2009
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonistsHao Zhang, Denis E Ryono, Pratik Devasthale, et al.
Journal of Medicinal Chemistry|February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesWei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.
Pageof 2